Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Pleural effusion in pneumonia].

T Schaberg1

  • 1Zentrum für Pneumologie, Diakoniekrankenhaus Rotenburg. schaberg@diako-online.de

Therapeutische Umschau. Revue Therapeutique
|November 7, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Joint Statement (DZK, DGRh, DDG) on the Tuberculosis Risk with Treatment Using Novel Non-TNF-Alpha Biologicals.

Pneumologie (Stuttgart, Germany)·2021
Same author

[Risk Assessment for Patients with Chronic Respiratory and Pulmonary Conditions in the Context of the SARS-CoV-2 Pandemic - Statement of the German Respiratory Society (DGP) with the Support of the German Association of Respiratory Physicians (BdP)].

Pneumologie (Stuttgart, Germany)·2020
Same author

[The New WHO Guidelines for Rapid Diagnostics and Treatment of Drug-Resistant Tuberculosis Commented for Germany, Austria and Switzerland].

Pneumologie (Stuttgart, Germany)·2020
Same author

[Treatment with Dexamethasone in Patients with COVID-19 - A Position Paper of the German Respiratory Society (DGP)].

Pneumologie (Stuttgart, Germany)·2020
Same author

[DZK Recommendations for Tuberculosis, BCG and COVID-19 in Germany - (Official Abbreviation of Coronavirus Disease 2019 Caused by the New Coronavirus SARS-CoV-2)].

Pneumologie (Stuttgart, Germany)·2020
Same author

[Kaleidoscope of History 2003 - 2016].

Pneumologie (Stuttgart, Germany)·2016

Parapneumonic effusions are common but usually benign. Early thoracentesis and pleural fluid analysis help categorize patients into risk groups for appropriate management, from observation to drainage or surgery.

Area of Science:

  • Pulmonology
  • Thoracic Medicine

Context:

  • Parapneumonic effusions are frequent complications of pneumonia, occurring in approximately 40% of cases.
  • While often clinically insignificant, prompt evaluation is crucial for identifying at-risk patients.

Purpose:

  • To outline diagnostic and risk stratification strategies for parapneumonic effusions.
  • To guide therapeutic interventions based on effusion characteristics and patient risk.

Summary:

  • Thoracentesis and pleural fluid analysis (pH, protein, glucose, microbiology, cytology) are essential investigations.
  • Patients are categorized into four risk groups based on effusion size, loculation, and fluid analysis.
  • Low-risk patients may require no intervention, while moderate-to-high-risk patients benefit from drainage therapy or video-assisted thoracoscopic surgery.

Related Experiment Videos

Impact:

  • Facilitates timely and appropriate management of parapneumonic effusions.
  • Improves patient outcomes by tailoring treatment to individual risk profiles.
  • Provides a framework for clinical decision-making in managing pleural space infections.